Jul. 31 at 12:22 AM
$ABCL
The market is valuing
$ABCL
based on what it used to be.
Unpredictable research revenue.
COVID-era biotech.
Years of heavy spending.
No approved internal medicines.
But look at what is happening now:
ABCL635 has entered Phase 2.
ABCL575 is in Phase 1.
Jazz paid
$56M upfront.
Vertex followed with another
$28M .
The company has approximately
$655M of available liquidity.
The risks haven’t disappeared. ABCL635 could fail, partnerships could stall and the cash burn remains significant.
But AbCellera is finally approaching the period when years of investment begin producing clinical data and commercial validation.
I am excited for the future.
